BenevolentAI Results Presentation Deck
BenevolentAl is a leading Al-enabled drug discovery &
development company with a platform-generated pipeline
DISCOVERY
Industry-leading Al platform uncovers
novel biology across diseases and
drug modalities
Expansive knowledge graph
with multimodal data
foundations
Disease and drug modality
agnostic
Generate predictions with the aim to
increase the probability of success
DEVELOPMENT
Portfolio of first-in-class and best-in-class
programs, discovered using our proprietary Al
platform
Discovery
BEN-2293 - Atopic Dermatitis
BEN-8744 - Ulcerative Colitis
BEN-9160 ALS
BEN- 28010 - Glioblastoma
asset in Phase II
Preclinical
1
3
15 Platform-generated drug programmes
assets in pre-IND/CTA
BenevolentAl Proprietary
Clinical
LO
Benevolent 5View entire presentation